Gsk Plc
Institutional manager — quarterly 13F holdings, Q ending 2026-03-31
Reported value
$599.2M
Q ending 2026-03-31
Prior quarter
$799.0M
Q ending 2025-12-31
Change
-25.0% QoQ
Positions
13
reported holdings
Largest positions
All 13 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
| Holding | Ticker | Type | Value ▼ | Shares |
|---|---|---|---|---|
| Crispr Therapeutics Ag | Shares | $153.2M | 3.2M | |
| Wave Life Sciences Ltd | Shares | $132.3M | 18.2M | |
| Biontech Se | BNTX | Shares | $79.1M | 890K |
| Vir Biotechnology Inc | VIR | Shares | $76.6M | 8.6M |
| Ideaya Biosciences Inc | IDYA | Shares | $44.4M | 1.3M |
| Lyell Immunopharma Inc | LYEL | Shares | $30.3M | 1.5M |
| Cytokinetics Inc | CYTK | Shares | $22.4M | 340K |
| Spero Therapeutics Inc | SPRO | Shares | $21.5M | 9.2M |
| Fulcrum Therapeutics Inc | FULC | Shares | $13.7M | 1.8M |
| Cvrx Inc | CVRX | Shares | $9.5M | 1.0M |
| Bicycle Therapeutics Plc | BCYC | Shares | $7.1M | 1.5M |
| Nkarta Inc | NKTX | Shares | $6.6M | 3.2M |
| Regenxbio Inc | RGNX | Shares | $2.3M | 271K |
Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.